Aktuella utlysningar, vecka 17, 2022
Grants Office tipsar om aktuella utlysningar.
Svenska och nordiska utlysningar
The 2022 Johnny Ludvigsson Prize for excellent research in childhood and adolescent diabetes
The prize winner should be a Nordic citizen and have conducted research in diabetes - clinically in children and adolescents and/or - epidemiologically on childhood and adolescent diabetes and/or - experimentally regarding type 1 diabetes. The use of biological samples from children and adolescents and a clinical association will be of great importance in the decision.
The prize winners should be nominated by at least three Nordic researchers in diabetes. The motivation should include a description of the scientific achievement (maximum 1000 words in English) and the most important (maximum 20) scientific publications.The award consists of a sum of 250.000 SEK and a diploma.The prize winner will give a 40-minute presentation on her or his research.
Closing date: 15 May 2022
If you have any questions, please contact the Swedish Child Diabetes Foundation office by e-mail firstname.lastname@example.org
Proof of concept within the infection area - Swedish Research Council
Supports projects that bridges the gap between basic research and utilisation or commercialisation of research results within the infection area. Grants are worth between SEK 500,000 and SEK 2 million for between one and two years.
Closing date: 24 May 2022
Project grant for research into the social consequences of digitalisation - Swedish Research Council
Supports research into the social consequences of digitalisation. Grants are worth between SEK 400,000 million to SEK 1.7 million per year for between one to four years.
Closing date: 24 May 2022
Diagnostics and surveillance networks call - Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)/ Swedish Research Council
Supports the creation of networks of leading experts and stakeholders with the aim of facilitating the development, optimisation and use of diagnostic and surveillance tools, technologies and systems to reduce the burden of antimicrobial resistance. The total budget is €1 million. Grants are worth up to €50,000 per network for one or two years.
Closing date: 14 June 2022
Startup grants - Jeanssons Stiftelser
Supports young researchers that are setting up their own research group. Eligible applicants should have a position connected to a university or institute, alternatively a clinical position at a university-affiliated hospital, and have received a PhD year 2016 or later.
Closing date: 21 June 2022
Research grants – ophthalmology -- Velux Foundation | Velux Stiftung, CH
These support projects that will induce a change of perspective in ophthalmology research and in the long run will provide innovative and effective solutions for the challenges in eye health specific to LMICs. The focus is on:
•interdisciplinary biomedical research projects in ophthalmology aiming to develop and assess new diagnostic, prevention, or treatment methods for eye diseases adapted to the local context and environment of LMICs;
•institutional research capacity building projects projects aiming at sustainably building, developing or reinforcing institutional structures enabling biomedical ophthalmology research.
Projects combining both aspects are welcome. Consortia of research groups with at least one partner based in an LMIC may apply. The involvement of Swiss partners is welcome. At least one PI or co-PI must be an established or leading researcher in ophthalmology.
Grants are worth between CHF 50,000 and CHF 100,000 each per year for between one and four years.
Closing date: 31 May 2022
Open funding call -- Bone Cancer Research Trust, GB
This supports high-impact, collaborative research related to primary bone cancer with a clear line of sight to patient benefit. Applications focusing on the development of new treatments for primary bone cancer, and those focused on early diagnosis, such as biomarker discovery and development, digital pathology, and imaging, are of particular interest. Applications on forms of primary bone cancer other than osteosarcoma are welcomed. The following grants are available:
•ideas grants, worth up to £25,000 each;
•project grants, worth up to £250,000 each.
UK and international candidates may apply. Senior postdocs may also apply as PI and have salary costs covered. Under the project grants stream, international applicants must have a UK-based collaborator.
Closing date: 1 June 2022
COMING SOON: Collaborative research grants -- International Brain Research Organization, NL
These foster international scientific collaboration and development of human resources by facilitating collaboration between emerging research groups or between an emerging research group and an established research group.
Applications must be made by collaborators from two different IBRO regions. Applicants may be from any IBRO region. Applicants must have been PIs for seven years or less. At least one research group should be a basic neuroscience laboratory.
Grants are worth up to €6,000 each.
Closing date: 11 June 2022 (Forecast). We have no information from the funder yet about the next call. Based on past experience, we forecast the deadline to be around June 2022.
Osteology researcher grants -- Osteology Foundation, CH
These support research on oral tissue regeneration. Topics may include:
•clinical aspects of hard and soft tissue biology;
•novel bone and soft tissue substitute materials;
•local factors affecting oral tissue regeneration;
•systemic diseases with an impact on oral tissue regeneration;
•pharmacological aspects of oral tissue regeneration;
•inflammatory conditions, such as periodontitis and peri-implantitis.
Applications are open to advanced researchers in the field of oral tissue regeneration and young researchers currently undergoing postgraduate education or within three years thereafter.
Grants for advanced researchers are worth up to CHF 100,000 each for projects lasting up to two years. Grants for young researchers are worth up to CHF 30,000 each for projects lasting up to one year.
Closing date: 15 June 2022
Heinrich Wieland prize -- Boehringer Ingelheim Foundation | Boehringer Ingelheim Stiftung, DE
The Boehringer Ingelheim Foundation invites nominations for the Heinrich Wieland prize. This recognises research on biologically active molecules and systems in the fields of chemistry, biochemistry and physiology, and their clinical importance.
Self-nominations are not permitted.
The prize is worth €100,000.
Closing date:1 June 2022
Coming soon: Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowships 2022
The MSCA 2022 Postdoctoral Fellowships program will open on May 12th after a delay. You can do a postdoc either within Europe with a 2-year fellowship (European Fellowship), or outside Europe (2 years) with a mandatory 1-year return phase to Europe with the 3-year Global Fellowship.
Closing date: 14September 2022
Coming soon: Marie Skłodowska-Curie Actions (MSCA) Doctoral Networks 2022 (former ITN)
The MSCA 2022 Doctoral Networks program will open 12th May, 2022. Principal Investigators participate or coordiantes a Consortium that applies for a training program for PhD students. The PhD students are to be recruited after the project is awarded. The MSCA Doctoral Networks program includes training networks, Industrial Doctorates and Joint Doctorates.
Closing date: 15 November 2022
Federal Funding agencies
Understanding the role of Gut Immune dysfunction and Gut Microbiome in pathogenesis of Central Nervous System co-morbidities in people living with HIV (R21 Clinical Trial Not Allowed), US
The purpose of this Funding Opportunity Announcement (FOA) is to support studies to investigate mechanisms by which the gut microbiome and gut immune system modulates the brain functions, circuits, neurotransmitters, signaling pathways and synaptic plasticity in the context of HIV and Anti-retroviral therapy. Exploratory and high-risk research projects are encouraged. Basic, preclinical, and clinical (e.g., pathophysiology or mechanisms) research in domestic and international settings are of interest. No clinical trials will be accepted for this FOA. Multidisciplinary research teams and collaborative alliances are encouraged but not required.
Examples of research areas that fall within the scope of this FOA include, but are not limited to:
- Basic and clinical studies (not clinical trials; see NIH Definition of a Clinical Trial) to identify mechanisms by which gut microbiota and gut immune system altered by HIV impact CNS outcomes in people living with HIV across the lifespan;
- Studies that model the impact of HIV and associated gut immune dysfunction on neurotransmitters, brain circuits, and networks regulating mood, cognition, and behavior;
- Studies to identify mechanistic biological signatures of gut microbiome associated immune dysfunction linked with adverse CNS outcomes in the context of HIV;
- Studies to identify modifiable pre-clinical targets, by deciphering the mechanisms involving gut microbiome and brain dysfunction unique to people living with HIV;
- Studies to understand the impact of ART medications on gut microbiome and gut immune system and resulting adverse CNS outcomes in the context of HIV;
- Studies to determine the modulatory effects of gut microbiota and gut immune dysfunction on hypothalamic-pituitary-adrenal (HPA) axis and the neuroendocrine system in the context of HIV.
Closing date: November 18, 2022. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-MH-22-230
Neuronal Vulnerability to Proteinopathies in Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (R01 Clinical Trial Not Allowed), US
The goal of this Funding Opportunity Announcement (FOA) is to define and characterize neuronal and glial cell populations that are vulnerable to Alzheimer's disease (AD) and AD-related dementias (ADRD) proteinopathies.
The goal of this FOA is to define and characterize neuronal and glial cell populations that are vulnerable to AD/ADRD proteinopathies. Research appropriate for this FOA may seek to:
- Establish comprehensive sets of data on neuronal and glial cells vulnerable to AD/ADRD proteinopathies based on single-cell transcriptomics or epigenetics signature
- Identify intrinsic morphological, electrophysiological, and biochemical properties of neurons vulnerable to proteinopathies
- Identify neural circuits and/or large-scale networks that contribute to vulnerability to proteinopathies
To standardize sequencing, cell clustering, and mapping methods, minimize variability, and maximize resource sharing, this FOA encourages collaboration with investigators who are currently funded by the BRAIN Initiative.
Closing date: July 15, 2022. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-AG-23-028
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional), US
This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with the development of a subsequent lethal phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms. For example, N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and/or digital pathomics, glycomics, or metabolomic imaging using analytic strategies such as artificial intelligence or virtual reality visualization techniques. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of potentially lethal cancer versus non-lethal disease, (2) minimize/better manage overdiagnosis and (3) reduce false positives and false negatives.
This FOA will utilize the NIH Research Project Grant (R01) mechanism and is suitable for projects where proof-of-principle of the individual proposed methodologies have already been established and supportive preliminary data are available.
Closing date: October 05, 2022, February 05, 2023, June 05, 2023 until June 05, 2025. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-22-131
Postdoctoral research fellowship
Dravet Syndrome Foundation, US
Postdoctoral Fellowship Awards are designed to support early-career researchers under the mentorship of an independent investigator. These fellowships are awarded to qualified applicants whose proposed projects investigate hypotheses directly related to Dravet syndrome.
Budget: Grants are awarded for $75,000 (beginning January 1 of each year), intended to support a full-time research effort with salary and benefits (no indirect costs).
Applicants should ensure their proposed project addresses the needs of the Dravet syndrome community and DSF’s mission to support research toward better treatments and a cure for Dravet syndrome.
Eligibility: Successful applicants hold an MD, PhD, or equivalent degree, are a clinical or post-doctoral fellow at an academic institution, may be US or foreign based, and do not hold a higher level faculty appointment.
Closing date: September 9, 2022.